– ID Business Solutions (IDBS) is a global provider of innovative enterprise data management, analytics and modelling software for R&D and science-driven companies
– Founded in 1989 by entrepreneur Neil Kipling, IDBS is headquartered in Guildford with a direct sales and support presence worldwide
– The company’s uniquely sophisticated platform technologies are used by more than 200 pharmaceutical companies, major healthcare providers and high tech companies to increase efficiency, reduce costs and improve the productivity of industrial R&D and clinical research
– Danaher Corporation is a global science and technology innovator with more than 20 operating companies spanning healthcare, environmental and industrial sectors
– The company is divided into the segments Life Sciences, Dental, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment operates under brands such as Pall, SCIEX, Molecular Devices, and Leica Microsystems
– Based in Washington, DC, the company is listed on the New York Stock exchange (NYSE:DHR) with a market capitalisation of c. $64bn
– The acquisition of IDBS will help provide the foundation of an informatics and knowledge management platform within Danaher’s Life Sciences segment
– IDBS will also be able to leverage the Danaher brand as it continues its transition to a SaaS-based delivery model
– The combined platform will make the digital lab of the future a reality by linking scientific instruments with informatics solutions to accelerate the speed of discovering, developing and producing new drugs and therapies
– Danaher approached IDBS with a pre-emptive proposal and Arma was engaged to advise, having already developed a strong relationship with the company
– Arma’s involvement resulted in a material improvement in value and also secured a full cash pay-out on completion (compared with the initial proposal), while de-risking the transaction through an expedited timetable
– This transaction highlights Arma’s long-standing track record of working with European clients to secure successful transatlantic deals with North American strategic acquirers
– The transaction also illustrates Arma’s leadership in advising companies in the Pharmatech sector, leveraging Arma’s deep domain expertise, relationships with (and access to) buyer ecosystems and first class execution capabilities